Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
13.73
USD
|
-3.72%
|
|
-11.30%
|
+28.32%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
102
|
156.8
|
26.8
|
457.2
|
819.6
|
-
|
-
|
Enterprise Value (EV)
1 |
102
|
156.8
|
26.8
|
457.2
|
819.6
|
819.6
|
819.6
|
P/E ratio
|
-1.84
x
|
-6.06
x
|
-0.72
x
|
-1.99
x
|
-6.87
x
|
-5.78
x
|
-4.75
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
32.6
x
|
102
x
|
-
|
55.6
x
|
EV / Revenue
|
-
|
-
|
-
|
32.6
x
|
102
x
|
-
|
55.6
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-8.02
x
|
-
|
-
|
-54.4
x
|
-23.4
x
|
-20.5
x
|
-14.6
x
|
FCF Yield
|
-12.5%
|
-
|
-
|
-1.84%
|
-4.27%
|
-4.88%
|
-6.83%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
10,542
|
12,100
|
12,129
|
42,730
|
59,694
|
-
|
-
|
Reference price
2 |
9.680
|
12.96
|
2.210
|
10.70
|
13.73
|
13.73
|
13.73
|
Announcement Date
|
3/25/21
|
3/28/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
14.02
|
8
|
-
|
14.75
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-12.26
|
-25.2
|
-36.9
|
-28.73
|
-114
|
-150.2
|
-179.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-204.94%
|
-1,424.8%
|
-
|
-1,219.36%
|
Earnings before Tax (EBT)
1 |
-
|
-17.84
|
-
|
-36.9
|
-106.8
|
-109.3
|
-143.5
|
-177.2
|
Net income
1 |
-10.44
|
-17.84
|
-24.71
|
-37.52
|
-106.8
|
-114.5
|
-149.1
|
-192.7
|
Net margin
|
-
|
-
|
-
|
-
|
-761.92%
|
-1,430.81%
|
-
|
-1,306.88%
|
EPS
2 |
-0.3200
|
-5.260
|
-2.140
|
-3.090
|
-5.380
|
-2.000
|
-2.375
|
-2.888
|
Free Cash Flow
1 |
-
|
-12.72
|
-
|
-
|
-8.399
|
-35
|
-40
|
-56
|
FCF margin
|
-
|
-
|
-
|
-
|
-59.92%
|
-437.5%
|
-
|
-379.76%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/9/20
|
3/25/21
|
3/28/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
2.364
|
-
|
-
|
3.826
|
2.5
|
2.25
|
2.25
|
1
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-7.723
|
-7.844
|
-11.65
|
-8.926
|
-8.534
|
-7.787
|
-4.471
|
-
|
-
|
-13.85
|
-31.04
|
-25.51
|
-26.44
|
-30.99
|
-40
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-189.13%
|
-
|
-
|
-362.02%
|
-1,241.77%
|
-1,133.7%
|
-1,174.98%
|
-3,099.47%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-
|
-8.533
|
-7.786
|
-4.27
|
-
|
-
|
-92.63
|
-30.37
|
-24.01
|
-25.08
|
-29.79
|
-37.8
|
Net income
1 |
-7.72
|
-7.852
|
-11.65
|
-8.924
|
-9.155
|
-7.786
|
-4.27
|
-
|
-4.345
|
-92.63
|
-45.55
|
-20.63
|
-22.01
|
-26.22
|
-37.8
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-180.63%
|
-
|
-
|
-2,421.17%
|
-1,822.11%
|
-917.07%
|
-978.3%
|
-2,621.62%
|
-
|
EPS
2 |
-0.6500
|
-0.6500
|
-0.9600
|
-0.7400
|
-0.7500
|
-0.6400
|
-0.3500
|
-0.4600
|
-0.3600
|
-4.220
|
-0.8100
|
-0.3725
|
-0.3825
|
-0.4550
|
-0.6700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/15/21
|
3/28/22
|
5/12/22
|
8/5/22
|
11/14/22
|
3/16/23
|
5/5/23
|
8/9/23
|
11/9/23
|
3/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-12.7
|
-
|
-
|
-8.4
|
-35
|
-40
|
-56
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.59
|
0.08
|
0.25
|
0.83
|
0.9
|
1.45
|
2.75
|
Capex / Sales
|
-
|
-
|
-
|
-
|
5.93%
|
11.25%
|
-
|
18.65%
|
Announcement Date
|
9/9/20
|
3/25/21
|
3/28/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
13.73
USD Average target price
35.33
USD Spread / Average Target +157.34% Consensus |
1st Jan change
|
Capi.
|
---|
| +28.32% | 820M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|